Roth Capital Upgrades Salix Pharmaceuticals (SLXP) to Buy
SLXP Hot Sheet
Rating Summary:9 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Roth Capital upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Hold to Buy. Price target $12.50.
To see more analyst ratings on SLXP Click Here.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract.
To see more analyst ratings on SLXP Click Here.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Wells Fargo Upgrades Aeropostale, Inc. (ARO) to Market Perform; Risk/Reward Even Given Improving Trends
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
UpgradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
